表紙
市場調査レポート

筋萎縮性側索硬化症:世界の治験レビュー

Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 239400
出版日 ページ情報 英文 118 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
筋萎縮性側索硬化症:世界の治験レビュー Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2014
出版日: 2014年05月21日 ページ情報: 英文 118 Pages
概要

当レポートでは、筋萎縮性側索硬化症に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤などの情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

  • 筋萎縮性側索硬化症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の上位5ヶ国
    • 欧州の上位5ヶ国
    • 北米の主要国
    • 中東・アフリカの主要国
    • 中南米の主要国

G7諸国での治験件数:中枢神経系疾患の治験全体における筋萎縮性側索硬化症の割合

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:中枢神経系疾患の治験全体における筋萎縮性側索硬化症の割合

E7諸国での治験件数:フェーズ(相)別

E7諸国での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • 筋萎縮性側索硬化症治療薬の治験に参加している上位企業

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概要
    • Biogen Idec Inc.
    • Cytokinetics, Incorporated
    • Trophos SA
    • Teva Pharmaceutical Industries Limited
    • Phoenix Neurological Associates, Ltd.
    • Novartis AG
    • NeuroNova AB
    • Neuralstem, Inc.
    • 三菱ケミカルホールディングス
    • Avanir Pharmaceuticals, Inc.
  • 代表的な研究機関・病院の治験の概要
    • Massachusetts General Hospital
    • Drexel University College of Medicine
    • National Institute of Neurological Disorders and Stroke
    • University of Miami
    • Mayo Clinic
    • Charite - Universitatsmedizin Berlin
    • National Institute of Environmental Health Sciences
    • U.S. Department of Veterans Affairs
    • Johns Hopkins University
    • Assistance Publique - Hopitaux de Paris

5つの代表的な治験のプロファイル

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC2151CTIDB

GlobalData's clinical trial report, "Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2014" provides data on the Amyotrophic Lateral Sclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Amyotrophic Lateral Sclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Amyotrophic Lateral Sclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Amyotrophic Lateral Sclerosis
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Amyotrophic Lateral Sclerosis
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Amyotrophic Lateral Sclerosis
    • Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS
    • Apr 28, 2014: FDA Approves Commencement of BrainStorm's Phase II ALS Clinical Trial in U.S.
    • Apr 25, 2014: Cytokinetics Announces Top-Line Results From BENEFIT-ALS
    • Mar 27, 2014: Cytokinetics Announces Initiation of Multiple Dose Phase I Clinical Trial of CK-2127107
    • Mar 17, 2014: Final Results Of Neuralstem Phase I Stem Cell Trial In Amyotrophic Lateral Sclerosis Published In Annals of Neurology
    • Mar 10, 2014: Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Biogen Idec Inc.
      • Clinical Trial Overview of Biogen Idec Inc.
      • Cytokinetics, Incorporated
      • Clinical Trial Overview of Cytokinetics, Incorporated
      • Trophos SA
      • Clinical Trial Overview of Trophos SA
      • Teva Pharmaceutical Industries Limited
      • Clinical Trial Overview of Teva Pharmaceutical Industries Limited
      • Phoenix Neurological Associates, Ltd.
      • Clinical Trial Overview of Phoenix Neurological Associates, Ltd.
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • NeuroNova AB
      • Clinical Trial Overview of NeuroNova AB
      • Neuralstem, Inc.
      • Clinical Trial Overview of Neuralstem, Inc.
      • Mitsubishi Chemical Holdings Corporation
      • Clinical Trial Overview of Mitsubishi Chemical Holdings Corporation
      • Avanir Pharmaceuticals, Inc.
      • Clinical Trial Overview of Avanir Pharmaceuticals, Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • Massachusetts General Hospital
      • Clinical Trial Overview of Massachusetts General Hospital
      • Drexel University College of Medicine
      • Clinical Trial Overview of Drexel University College of Medicine
      • National Institute of Neurological Disorders and Stroke
      • Clinical Trial Overview of National Institute of Neurological Disorders and Stroke
      • University of Miami
      • Clinical Trial Overview of University of Miami
      • Mayo Clinic
      • Clinical Trial Overview of Mayo Clinic
      • Charite - Universitatsmedizin Berlin
      • Clinical Trial Overview of Charite - Universitatsmedizin Berlin
      • National Institute of Environmental Health Sciences
      • Clinical Trial Overview of National Institute of Environmental Health Sciences
      • U.S. Department of Veterans Affairs
      • Clinical Trial Overview of U.S. Department of Veterans Affairs
      • Johns Hopkins University
      • Clinical Trial Overview of Johns Hopkins University
      • Assistance Publique - Hopitaux de Paris
      • Clinical Trial Overview of Assistance Publique - Hopitaux de Paris
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Biogen Idec Inc., 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytokinetics, Incorporated, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Trophos SA, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Teva Pharmaceutical Industries Limited, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Phoenix Neurological Associates, Ltd., 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by NeuroNova AB, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Neuralstem, Inc., 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Mitsubishi Chemical Holdings Corporation, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Avanir Pharmaceuticals, Inc., 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Drexel University College of Medicine, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Miami, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Charite - Universitatsmedizin Berlin, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Environmental Health Sciences, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014*

List of Figures

  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
  • Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top